The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Recent advances in the treatment of IBD: Targets, mechanisms and related therapies
Open accessAbstract
Inflammatory bowel disease (IBD), as a representative inflammatory disease, currently has multiple effective treatment options available and new therapeutic strategies are being actively explored to further increase the treatment options for patients with IBD. Furthermore, biologic agents and small molecule drugs developed for ulcerative colitis (UC) and Crohn's disease (CD) have evolved toward fewer side effects and more accurate targeting. Novel inhibitors that target cytokines (such as IL-12/23 inhibitors, PDE4 inhibitors), integrins (such as integrin inhibitors), cytokine signaling pathways (such as JAK inhibitors, SMAD7 blocker) and cell signaling receptors (such as S1P receptor modulator) have become the preferred treatment choice for many IBD patients. Conventional therapies such as 5-aminosalicylic acid, corticosteroids, immunomodulators and anti-tumor necrosis factor agents continue to demonstrate therapeutic efficacy, particularly in combination with drug therapy. This review integrates research from chemical, biological and adjuvant therapies to evaluate current and future IBD therapies, highlighting the mechanism of action of each therapy and emphasizing the potential of development prospects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The four epidemiological stages in the global evolution of inflammatory bowel disease
Kaplan, G. G., & Windsor, J. W. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00360-x · Cited by 1,351
Janus kinases in immune cell signaling
Ghoreschi, K., Laurence, A., & O’Shea, J. J. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00754.x · Cited by 1,149
Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn’s Disease
Sandborn, W. J., Feagan, B. G., Loftus, E. V., Peyrin-Biroulet, L., Van Assche, G., D’Haens, G., Schreiber, S., Colombel, J.-F., Lewis, J. D., Ghosh, S., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.047 · Cited by 322
Dietary guidance from the international organization for the study of inflammatory bowel diseases
Levine, A., Rhodes, J. M., Lindsay, J. O., Abreu, M. T., Kamm, M. A., Gibson, P. R., Gasche, C., Silverberg, M. S., Mahadevan, U., Boneh, R. S., et al. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.01.046 · Cited by 297
Zhang, X.-F., Guan, X.-X., Tang, Y.-J., Sun, J.-F., Wang, X.-K., Wang, W.-D., & Fan, J.-M. (2021) · European Journal of Nutrition · doi:10.1007/s00394-021-02503-5 · Cited by 193
Cited by
Ulcerative colitis: clinical biomarkers, therapeutic targets, and emerging treatments
Wangchuk, P., Yeshi, K., & Loukas, A. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.08.003 · Cited by 333
Metadata
- Authors
- Liu, J., Di, B., & Xu, L.-L.
- Venue
- Cytokine & Growth Factor Reviews
- Publisher
- Elsevier BV
- Published
- 2023-06
- Volume
- 71-72
- Pages
- 1-12
- ISSN
- 1359-6101 (ISSN-L)
- OpenAlex
- W4384023470
- Cited by
- 166
- References
- 5
- FWCI
- 8.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recent advances in the treatment of IBD: Targets, mechanisms and related therapies. https://app.cochat.ai/papers/10.1016/j.cytogfr.2023.07.001
- The paper
- Liu, J., Di, B., & Xu, L.-L. (2023). Recent advances in the treatment of IBD: Targets, mechanisms and related therapies. Cytokine & Growth Factor Reviews. https://doi.org/10.1016/j.cytogfr.2023.07.001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.